Title |
Natural Killer Cell Immunotherapy: From Bench to Bedside
|
---|---|
Published in |
Frontiers in immunology, June 2015
|
DOI | 10.3389/fimmu.2015.00264 |
Pubmed ID | |
Authors |
Anna Domogala, J. Alejandro Madrigal, Aurore Saudemont |
Abstract |
The potential of natural killer (NK) cells to target numerous malignancies in vitro has been well documented; however, only limited success has been seen in the clinic. Although NK cells prove non-toxic and safe regardless of the cell numbers injected, there is often little persistence and expansion observed in a patient, which is vital for mounting an effective cellular response. NK cells can be isolated directly from peripheral blood, umbilical cord blood, or bone marrow, expanded in vitro using cytokines or differentiated in vitro from hematopoietic stem cells. Drugs that support NK cell function such as lenalidomide and bortezomib have also been studied in the clinic, however, the optimum combination, which can vary among different malignancies, is yet to be identified. NK cell proliferation, persistence, and function can further be improved by various activation techniques such as priming and cytokine addition though whether stimulation pre- or post-injection is more favorable is another obstacle to be tackled. Here, we review the various methods of obtaining and activating NK cells for use in the clinic while considering the ideal product and drug complement for the most successful cellular therapy. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Germany | 1 | <1% |
Unknown | 100 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 31 | 30% |
Student > Ph. D. Student | 23 | 23% |
Student > Bachelor | 11 | 11% |
Student > Master | 9 | 9% |
Student > Doctoral Student | 6 | 6% |
Other | 7 | 7% |
Unknown | 15 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 21 | 21% |
Agricultural and Biological Sciences | 18 | 18% |
Medicine and Dentistry | 18 | 18% |
Immunology and Microbiology | 11 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Other | 12 | 12% |
Unknown | 18 | 18% |